Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Clint Winters, Medical Scientist, Announces Patent Filing on CONO1000™, A Novel Conolidine Pain Relief Active Ingredient

Winters Biotechnology, led by Medical Scientist Clint Winters, has announced patent filings in relation to CONO1000™, the first natural conolidine ingredient to be produced and available in the world health market.


News provided by

Winters Biotechnology

Nov 02, 2021, 05:00 ET

Share this article

Share toX

Share this article

Share toX


ALPHARETTA, Ga., Nov. 2, 2021 /PRNewswire-PRWeb/ -- Winters Biotechnology has announced patent filings for CONO1000™, a novel dietary ingredient featuring the conolidine alkaloid formulated for natural pain relief.

For years, conolidine, a naturally occurring alkaloid found inside the bark of the Tabernaemontana divaricata tree, has been studied for its ability to relieve pain.

“Conolidine has been incredibly intriguing to me since I first read the initial pain relief research. I have worked very hard to develop a natural version. From day 1, I knew this innovation was special as it could provide safe and powerful relief to millions struggling with daily pain." - Clint W.

Post this

It was initially investigated in 2011 after being compared therapeutically to morphine without exhibiting side effects or addiction risk in rat models.

In 2019, Australian scientists discovered it had similar pain-killing modalities as CBD.

Then in early 2021, scientists reconfirmed its ability to significantly relieve chronic pain as they pinpointed its ability to affect the ACKR3/CXCR7 receptor.

However, until recently, most scientific innovation has centered around isolating and synthesizing conolidine for an eventual pharmaceutical application.

However, Clint Winters and Winters Biotechnology have been studying natural conolidine extractions since 2017 in hopes of developing a novel natural ingredient.

Earlier this year, they announced patents on a novel nutrient extraction system named the DualPolar™ extraction method, which is used to create a full-spectrum extraction of Tabernaemontana divaricata.

Clint Winters, now considered the world's leading authority on natural conolidine, had this to say about the innovation.

"Conolidine has been incredibly intriguing to me since I first read the initial pain relief research. I have worked very hard to develop a natural version. From day 1, I knew this innovation was special as it could provide safe and powerful relief to millions struggling with daily pain. My firm and I took a much different approach than other scientists. I focused on creating a full-spectrum natural extraction of Tabernaemontana divaricata. After nearly three years of research, I am proud to show CONO1000™ to the world."

Thanks to the DualPolar™ extraction method, Winters Biotechnology has successfully developed a full-spectrum alkaloid extraction.

CONO1000™ not only includes the conolidine alkaloid, but it also includes 65 other naturally occurring alkaloids found in this potent medicinal plant.

This innovation means that the potent conolidine alkaloid can finally be accessed in a natural state.

Clint Winters went on to say,

"I truly believe CONO1000™ is the future of safe and natural pain relief. In tests, we have been able to develop sublingual and topical applications with extraordinary efficacy. I have watched this powerful ingredient dramatically change lives in our private tests. I am excited to watch it help millions in the years to come as it becomes available worldwide."

Currently, CONO1000™ is the first and only natural conolidine ingredient available in the world.

Since it is not synthetic, it will not require a prescription, making it available immediately.

Winters Biotechnology is currently in discussions with multiple leading manufacturers regarding the production and distribution of CONO1000™.

This novel ingredient should be available worldwide by 2022 in all major world markets.

Additionally, Winters Biotechnology is slated to release enhanced versions of CONO1000™ within the next twelve months as support ingredients are identified.

You can learn more about Clint Winters, Winters Biotechnology and CONO1000™ by visiting WintersBiotechnology.com.

Winters Biotechnology is a medical innovation firm based in Alpharetta, GA. The company is wholly owned by Private Equity Firm Winters Capital Investments and was founded by medical scientist, entrepreneur, entertainment figure, and investor Clint Winters. The firm focuses on creating unique dietary ingredients and innovative nutraceutical and pharmaceutical manufacturing methods that manufacturers can license.

In addition to the CONO1000™ patent filing, Mr. Winters has also filed two patents with the conolidine alkaloid natural pain killer and an additional patent in relation to the enhancement of CBD.

The firm is currently developing two novel drug delivery mechanisms that will be under patent by the end of the year.

Earlier in his career, Mr. Winters developed and patented a non-thermal infrared technology that is now being used for accelerated healing and pain relief.

Media Contact

Spencer Jargon, Winters Biotechnology, 1-877-678-9719, [email protected]

SOURCE Winters Biotechnology

Related Links

https://wintersbiotechnology.com/

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.